The European journal of cardiovascular medicine最新文献_第8页

INTRAMYOCARDIAL STEM CELL TRANSPLANTATION IN CARDIAC SURGERY: FROM PRECLINICAL BACKGROUNDS TO THE PERFECT TRIAL 心脏手术中心肌内干细胞移植:从临床前背景到完美试验

The European journal of cardiovascular medicine Pub Date : 2011-02-20 DOI: 10.5083/EJCM.20424884.20

P. Donndorf, Prof. Dr. med. Gustav Steinhoff

引用次数: 2

Malign Asystole During Head-up Tilt Test: A Case Report and Overview. 平视倾斜试验中恶性心脏骤停一例报告及综述。

The European journal of cardiovascular medicine Pub Date : 2011-02-01 DOI: 10.5083/ejcm.20424884.22

Yahya Islamoglu, Musa Cakici, Hayri Alici, Vedat Davutoglu

引用次数: 0

Malign Asystole During Head-up Tilt Test: A Case Report and Overview. 平视倾斜试验中恶性心脏骤停一例报告及综述。

The European journal of cardiovascular medicine Pub Date : 2011-02-01 DOI: 10.1016/S0167-5273(11)70482-X

Y. Islamoğlu, M. Çakıcı, H. Alıcı, V. Davutoglu

引用次数: 2

Effective Lipid-lowering Therapy in High-risk Patients 高危患者的有效降脂治疗

The European journal of cardiovascular medicine Pub Date : 2011-01-25 DOI: 10.5083/EJCM.20424884.211

J. Kastelein, B. Arsenault, J. Tardif

引用次数: 0

Cor Triatriatum Sinistrum: Classification and Imaging Modalities. 心房三裂:分类和成像方式。

The European journal of cardiovascular medicine Pub Date : 2011-01-01 DOI: 10.5083/ejcm.20424884.21

Pierre Nagib Nassar, Righab Haidar Hamdan

引用次数: 83

Emerging Risk Stratification in Syncope. 晕厥新出现的危险分层。

The European journal of cardiovascular medicine Pub Date : 2010-07-01 DOI: 10.5083/ejcm.20424884.11

S V Jamalyan, L A Khachatryan

引用次数: 3

Inherited Cardiac Diseases: Preimplantation Genetic Diagnosis - An Attractive Alternative to Prenatal Diagnosis 遗传性心脏病:植入前遗传学诊断-产前诊断的一个有吸引力的选择

The European journal of cardiovascular medicine Pub Date : 2010-06-20 DOI: 10.5083/EJCM.20424884.09

J. Theilade, M. Duno, S. Ziebe, H. Bundgaard

引用次数: 0

The Clinical Benefit of Omega-3 PUFA Ethyl Esters Omega-3 PUFA乙酯的临床益处

The European journal of cardiovascular medicine Pub Date : 2010-06-20 DOI: 10.5083/ejcm.20424884.07

M. Cowie

{"title":"The Clinical Benefit of Omega-3 PUFA Ethyl Esters","authors":"M. Cowie","doi":"10.5083/ejcm.20424884.07","DOIUrl":"https://doi.org/10.5083/ejcm.20424884.07","url":null,"abstract":"Chronic heart failure, a syndrome of cardiac dysfunction associated with breathlessness, effort intolerance and fluid retention, affects 1-2% of the population. The most frequent cause is impairment of systolic function of the left ventricle, usually due to coronary artery disease. Hypertension or diabetes often co-exist. Treatment of heart failure (HF) is centred on correction of any reversible pathology and antagonism of the intense neurohormonal activation triggered by the cardiac dysfunction. This is achieved by angiotensin converting enzyme inhibitors (or angiotensin receptor blockers), beta-blockers and in more severe cases, an aldosterone antagonist. The prognosis of HF remains poor – with a first year mortality of over 30%, reducing to 10% per annum thereafter. Death is usually due to either progressive pump failure or sudden death, which is presumably arrhythmic in origin. A randomised double-blind controlled trial of 1g daily of omega-3 polyunsaturated fatty acids (PUFA) ethyl esters in almost 7000 patients with symptomatic chronic heart failure of any cause reported a 9% relative risk reduction in mortality (P=0.04) and 8% relative risk reduction in mortality or cardiovascular hospitalisation (P=0.009)(GISSI-HF). In absolute terms, 56 patients need to be treated for 3.9 years to prevent one death. International guidelines recommend the prescription of 1g daily of n-3 PUFA as an adjuvant to secondary prevention in patients after myocardial infarction (based on the results of GISSI-Prevenzione, published in 1999) and for those with hypertriglyceridaemia, but are likely to be updated to recommend this therapy for patients with heart failure also.","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2010-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5083/ejcm.20424884.07","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70860170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark 丹麦西部佐他莫司洗脱和西罗莫司洗脱冠脉支架的注册和随机比较综述

The European journal of cardiovascular medicine Pub Date : 2010-06-20 DOI: 10.5083/EJCM.20424884.06

M. Maeng, A. Kaltoft, L. Jensen, P. Thayssen, N. Holm, E. Christiansen, L. Krusell, C. Terkelsen, S. Kristensen, H. Bøtker, J. Lassen, L. Thuesen, H. Hansen, J. Ravkilde

{"title":"Review of Registry and Randomised Comparisons of Zotarolimus-eluting and Sirolimus-eluting Coronary Stents in Western Denmark","authors":"M. Maeng, A. Kaltoft, L. Jensen, P. Thayssen, N. Holm, E. Christiansen, L. Krusell, C. Terkelsen, S. Kristensen, H. Bøtker, J. Lassen, L. Thuesen, H. Hansen, J. Ravkilde","doi":"10.5083/EJCM.20424884.06","DOIUrl":"https://doi.org/10.5083/EJCM.20424884.06","url":null,"abstract":"The safety and efficacy of coronary stents utilised for treatment of ischaemic heart disease have been extensively evaluated. In comparison with bare metal stents, first-generation drug-eluting stents more than halved the need for target lesion revascularisation (TLR). However, the long-term safety has been questioned as the first-generation drug-eluting stents seemed to be associated with a small, but increased, risk of (very) late stent thrombosis. The latter may be related to an inflammatory reaction caused by the polymer used for drug release control. The second-generation zotarolimuseluting Endeavor® stent was believed to represent a safer alternative. We present an overview of our results from a large randomised trial and a large registry, both of which compared clinical outcomes with the Endeavor® and the first-generation sirolimus-eluting Cypher® stent. Both studies indicated that the Endeavor® stent had higher risks of adverse outcomes. We discuss these data in the light of the current available data from other randomised comparisons of these two drug-eluting stents.","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"1 1","pages":"18-22"},"PeriodicalIF":0.0,"publicationDate":"2010-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5083/EJCM.20424884.06","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70859791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents? 药物洗脱支架治疗急性冠脉综合征:第二代支架有支架血栓形成的风险吗?

The European journal of cardiovascular medicine Pub Date : 2010-06-01 DOI: 10.5083/ejcm.20424884.10

Kamal Chitkara, Kushal Pujara

{"title":"Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents?","authors":"Kamal Chitkara, Kushal Pujara","doi":"10.5083/ejcm.20424884.10","DOIUrl":"https://doi.org/10.5083/ejcm.20424884.10","url":null,"abstract":"<p><p>Over the past decade, the advent of drug-eluting stents (DES) has revolutionised the field of interventional cardiology by having a major impact on patient care through their efficacy in reducing the need for repeat revascularisation. A number of stents capable of delivering an anti-proliferative agent designed to prevent neointimal hyperplasia, the principal mechanism of restenosis after stenting, have been evaluated; four of these devices are currently approved by the U.S. Food and Drug Administration (FDA). Bare metal stent (BMS) and first-generation DES, such as sirolimus-eluting (SES-Cypher(®)) and paclitaxel-eluting stents (PES-Taxus(®)), have further improved results of percutaneous coronary intervention (PCI) by improving early results and reducing the risk of restenosis. However, there is currently debate on the safety of these first-generation DES, given the potential for late stent thrombosis (LST), especially after discontinuation of dual anti-platelet therapy. Second-generation DES, such as zotarolimus-eluting (ZES-Endeavor(®)) and everolimus-eluting stents (EES-Xience V(®)), are become available in the USA and/or Europe. Recently, long-term results comparing DES with BMS in patients with ST-segment-elevation MI (STEMI) have raised some questions about the long-term risks of the drug-eluting devices. It may be useful to pause, reflect for a moment, and consider some recent pertinent results regarding their wider use. This systematic review tries to provide a concise and critical appraisal of the data available to compare first and second generation stents especially to assess risk of stent thrombosis (ST) with second-generation DES.</p>","PeriodicalId":75000,"journal":{"name":"The European journal of cardiovascular medicine","volume":"1 2","pages":"20-24"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5083/ejcm.20424884.10","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29867673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11